Ravi Menghani
Ophthalmology · Long Beach, CANPI 1518285360
Payments from drug & device makers
Across 117 payments — averaging $22.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$520
- Alcon$415
- Mallinckrodt Hospital Products Inc.$236
- Novartis$216
- Carl Zeiss Meditec, Inc.$178
- Tarsus Pharmaceuticals, Inc.$162
- plus $915 from 16 others
What the payments were for
- Food & beverage$2,60399%
- Gifts$391%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 26 | $520 |
| Alcon | 20 | $415 |
| Mallinckrodt Hospital Products Inc. | 9 | $236 |
| Novartis | 17 | $216 |
| Carl Zeiss Meditec, Inc. | 2 | $178 |
| Tarsus Pharmaceuticals, Inc. | 5 | $162 |
| AbbVie(2 entities) | 6 | $133 |
| Eyevance Pharmaceuticals LLC | 2 | $124 |
| Amgen(2 entities) | 5 | $120 |
| Dompe US, Inc. | 4 | $92 |
| Harrow Eye, LLC | 3 | $86 |
| Oyster Point Pharma, Inc. | 3 | $64 |
| Thea Pharma Inc. | 2 | $47 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $44 |
| Bausch & Lomb Americas Inc. | 2 | $42 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Rayner Intraocular Lenses Limited | 1 | $28 |
| Shire North American Group Inc | 1 | $25 |
| Kala Pharmaceuticals, Inc. | 2 | $24 |
| Aerie Pharmaceuticals, Inc. | 1 | $20 |
| Optos, Inc. | 1 | $14 |
| ANI Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VisuMax$123
- ARTEVO 800$123
- Flarex$110
How this compares
$2,642 in reported general payments places this provider in the 60th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 1,258 | $944,657 |
| Cyclosporine | 650 | $280,469 |
| CequaCyclosporine | 230 | $123,755 |
| Fluorometholone | 732 | $69,162 |
| VyzultaLatanoprostene Bunod | 109 | $52,982 |
| XiidraLifitegrast | 80 | $52,649 |
| LumiganBimatoprost | 107 | $42,837 |
| Azelastine Hcl | 1,931 | $40,333 |
| Prednisolone Acetate | 494 | $28,581 |
| RhopressaNetarsudil Mesylate | 47 | $27,576 |
| MieboPerfluorohexyloctane/Pf | 30 | $24,463 |
| Restasis MultidoseCyclosporine | 33 | $19,869 |
| Latanoprost | 1,030 | $12,951 |
| CombiganBrimonidine Tartrate/Timolol | 29 | $12,092 |
| Alphagan PBrimonidine Tartrate | 27 | $9,609 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Restasis Multidose, Combigan, Alphagan P | $133 | $1,029,0641,454 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra, Miebo | $42 | $130,094219 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $520 | $123,755230 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $20 | $27,57647 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $44 | $5,43313 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $64 | $3,58611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Long Beach
- Julie GasperiniLong Beach$814K
- Carl HartmanLong Beach$716K
- Dan TranLong Beach$649K
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.